NCT04083963View on ClinicalTrials.gov

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 9, 2019

Primary Completion Date

September 27, 2026

Study Completion Date

September 27, 2026

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Carboplatin

Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.

DRUG

Paclitaxel

Paclitaxel will be given weekly along with carboplatin for 12 weeks.

DRUG

Doxorubicin

Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.

DRUG

Cyclophosphamide

Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.

Trial Locations (1)

60612

University of Illinois, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER

NCT04083963 - Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter